[Biochemical recurrence in patients with prostate cancer after radical treatment. Comparative study of prostatectomy vs. radiotherapy].
OBJECTIVE
To compare the biochemical relapse-free survival between radical prostatectomy and radiotherapy in patients with localized prostate cancer of low and intermediate recurrence risk.


METHODS
A retrospective study of 435 patients with localized prostate cancer, radical prostatectomy was performed in 65% of patients and radiotherapy was in 35%. The Kaplan-Meier Estimator was used to assess the biochemical relapse-free survival and long-rank test, Breslow and Tarone-Ware to evaluate the differences between the groups with confidence intervals at 95%.


RESULTS
The median follow-up of the series was 60 months (3-106). Biochemical recurrence was diagnosed in 21% of patients: 22% of those were treated with prostatectomy and 19% with radiotherapy (p = 0.47). No significant differences were observed according to risk group (p = 0.60 in the low risk and p = 0.32 in the intermediate risk). Tree, five and seven-year actuarial biochemical recurrence-free survival for prostatectomy were 84%, 75%and 70%, while for radiotherapy were 97%, 84% and 64% respectively.


CONCLUSIONS
There are no significant differences in actuarial biochemical recurrence free survival in patients with localized prostate cancer of low and intermediate risk treated with prostatectomy or radiation therapy. Due to the crossing of the survival curves we do not rule out that with longer follow-up these results could be modified.
Servicios de Urología y Oncología Radioterápica, Hospital General Universitario Gregorio Marañón, Madrid, España. felipeherranz@telefonica.net
Felipe Herranz
FH
Amo
Carmen González
CG
San Segundo
Eva V Paños
EV
Facundo
Ana Alvarez
AA
González
Marina Gomez
MG
Espi
Enrique Lledó
EL
García
Juan Tabares
JT
García
Fernando Verdú
FV
Tartajo
Carlos Fernández
CF
Hernández
D000368:Aged; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000453:epidemiology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000453:epidemiology / Q000532:radiotherapy* / Q000601:surgery*; D012189:Retrospective Studies
D017430:Prostate-Specific Antigen